Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 9, September, p. 1253–1257

doi: 10.17219/acem/69921

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations

Ewa Wielosz1,A,B,C,D,E,F, Maria Majdan1,A,C,E,F, Magdalena Dryglewska1,B,C, Robert Zwolak1,B,C,E

1 Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland

Abstract

Background. It is known that anti-citrullinated protein (a-CCP) antibodies and rheumatoid factor (RF) can be present in systemic sclerosis (SSc) patients, particularly with joint involvement.
Objectives. The aim of the study was to assess the prevalence of a-CCP antibodies and immunoglobulin M class (IgM) RF, and the relationships between their presence and joint manifestations in patients with SSc.
Material and Methods. The study included 100 European Caucasian SSc patients hospitalized consecutively in the Department of Rheumatology and Connective Tissue Diseases (Lublin, Poland). Anti-citrullinated protein antibodies and IgM RF were determined using a commercial enzyme-linked immunosorbent assay (ELISA) test.
Results. Anti-citrullinated protein antibodies were found in 10 out of 100 (10%) SSc patients and IgM RF in 71 out of 100 (71%) SSc patients. In the study, 90/100 (90%) SSc patients had joint manifestations (arthralgia or arthritis), 34/100 (34%) had arthritis and 6/100 (6%) had a systemic sclerosis-rheumatoid arthritis (SSc-RA) overlap syndrome. Significantly higher a-CCP antibody levels (p = 0.012), erythrocyte sedimentation rate (ESR) (p = 0.029) and C-reactive protein (CRP) levels (p = 0.020) were observed in the SSc group with arthritis. A significant correlation was found between the group with arthritis and the presence of a-CCP antibodies, and between the arthralgia group and the presence of IgM RF.
Conclusion. The prevalence of RF and a-CCP antibodies is relatively high in SSc, and joint involvement occurs frequently. There was a significantly higher prevalence of IgM RF in the group with joint manifestations. About 1/3 of SSc patients had symptoms of arthritis. Arthritis is connected with the presence of a-CCP antibodies, while arthralgia is connected with the presence of IgM RF.

Key words

systemic sclerosis, arthritis, rheumatoid factor, anti-citrullinated protein antibodies, arthralgia

References (28)

  1. Ingegnoli F, Galbiati V, Zeni S, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol. 2007;26:510–514.
  2. Polimeni M, Feniman D, Skare TS, Nisihara RM. Anti-cyclic citrullinated peptide antibodies in scleroderma patients. Clin Rheumatol. 2012;31:877–880.
  3. Schmeiser T, Pons-Kühnemann J, Özden F, Müller-Ladner U, Dinser R. Arthritis in patients with systemic sclerosis. Eur J Intern Med. 2012; 23:25–29.
  4. Lima TR, Guimarães FS, Silva LA, Silva DP, Menezes SL, Lopes AJ. Relationship between functional capacity, joint mobility and pulmonary function in patients with systemic sclerosis. J Bodyw Mov Ther. 2015;19:17–24.
  5. Chevreul K, Brigham KB, Gandré C, Mouthon L; BURQOL-RD Research Network. The economic burden and health-related quality of life associated with systemic sclerosis in France. Scand J Rheumatol. 2014; 18:1–9.
  6. Arslan Tas D, Erken E, Sakalli H, Yucel AE. Evaluating hand in systemic sclerosis. Rheumatol Int. 2012;32:3581–3586.
  7. Mouthon L. Hand involvement in systemic sclerosis. Presse Med. 2013; 42:1616–1626.
  8. Marrone M, Chialà A, Tampoia M, et al. Prevalence of anti-CCP antibodies in systemic sclerosis. Reumatismo. 2007;59:20–24.
  9. Horimoto AM, Costa IP. Overlap between systemic sclerosis and rheumatoid arthritis: A distinct clinical entity? Rev Bras Reumatol. 2015;4: 482–504.
  10. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol. 2006;24:374–392.
  11. Arslan Tas D; Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–590.
  12. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol. 2003;21: 32–38.
  13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324.
  14. Payet J, Goulvestre C, Bialé L, et al. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: Experience with 1162 patients. J Rheumatol. 2014;41:2395–2402.
  15. Ueda-Hayakawa I, Hasegawa M, Kumada S, et al. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford). 2010;49:2135–2139.
  16. Stamenković B, Stanković A, Dimić A, et al. The clinical significance of antibody determination to cyclic citrullinated peptides in systemic sclerosis. Srp Arh Celok Lek. 2012;140:350–354.
  17. Morita Y, Muro Y, Sugiura K, Tomita Y. Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol. 2008;26:542–547.
  18. Allali F, Tahiri L, Senjari A, Abouqal R, Hajjaj-Hassouni N. Erosive arthropathy in systemic sclerosis. BMC Public Health. 2007;7:260–266.
  19. Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology (Oxford). 2012;51: 1347–1356.
  20. Iagnocco A, Vavala C, Vasile M, Stefanantoni K, Valesini G, Riccieri V. Power Doppler ultrasound of the hand and wrist joints in systemic sclerosis. Clin Exp Rheumatol. 2013;31:89–95.
  21. Gutierrez M, Pineda C, Cazenave T, et al. Ultrasound in systemic sclerosis. A multi-target approach from joint to lung. Clin Rheumatol. 2014;33:1039–1047.
  22. Stoenoiu MS, Houssiau FA, Lecouvet FE. Tendon friction rubs in systemic sclerosis: A possible explanation – an ultrasound and magnetic resonance imaging study. Rheumatology (Oxford). 2013;52:529–533.
  23. Avouac J, Walker UA, Hachulla E, et al; EUSTAR collaborators. Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study. Ann Rheum Dis. 2016;75:103–109.
  24. Bálint Z, Farkas H, Farkas N, et al. A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis. Clin Exp Rheumatol. 2014;32:68–74.
  25. Ingegnoli F, Boracchi P, Ambrogi F, Gualtierotti R, Galbiati V, Meroni PL. Hand impairment in systemic sclerosis: Association of different hand indices with organ involvement. Scand J Rheumatol. 2010;39: 393–397.
  26. Fett N. Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies. Clin Dermatol. 2013;31: 432–437.
  27. Grant-Kels JM, Rothe MJ, Mease P. Rheumatology and dermatology: Part 1. Clin Dermatol. 2006;24:347.
  28. Generini S, Steiner G, Miniati I, et al. Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology (Oxford). 2009;48:920–925.
© Wroclaw Medical University